| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 30 | 2024 | 108 | 6.650 |
Why?
|
| Cadherins | 14 | 2024 | 174 | 5.520 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2024 | 194 | 2.280 |
Why?
|
| Arthritis, Rheumatoid | 14 | 2024 | 277 | 2.090 |
Why?
|
| Macrophages | 5 | 2024 | 642 | 1.860 |
Why?
|
| Skin | 7 | 2024 | 527 | 1.570 |
Why?
|
| Antirheumatic Agents | 7 | 2023 | 125 | 1.460 |
Why?
|
| Autoantibodies | 11 | 2019 | 434 | 1.410 |
Why?
|
| Skin Diseases | 3 | 2018 | 132 | 1.180 |
Why?
|
| Autoimmune Diseases | 7 | 2024 | 260 | 1.180 |
Why?
|
| Pulmonary Fibrosis | 4 | 2022 | 114 | 1.160 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 3203 | 1.160 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 467 | 1.160 |
Why?
|
| Fibroblasts | 11 | 2024 | 888 | 1.120 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 4467 | 1.090 |
Why?
|
| Rheumatic Diseases | 5 | 2024 | 70 | 1.060 |
Why?
|
| Fibrosis | 9 | 2024 | 447 | 1.030 |
Why?
|
| Synovitis | 2 | 2020 | 25 | 0.950 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 219 | 0.940 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2024 | 154 | 0.940 |
Why?
|
| Dendritic Cells | 3 | 2024 | 417 | 0.870 |
Why?
|
| Liver | 2 | 2022 | 1758 | 0.850 |
Why?
|
| Phagocytosis | 2 | 2024 | 172 | 0.840 |
Why?
|
| Extracellular Matrix | 4 | 2019 | 241 | 0.770 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 15 | 0.770 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 1725 | 0.720 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 236 | 0.710 |
Why?
|
| Patient Compliance | 1 | 2024 | 471 | 0.700 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.700 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 367 | 0.690 |
Why?
|
| Uveitis | 1 | 2020 | 36 | 0.690 |
Why?
|
| Sarcoidosis | 1 | 2020 | 61 | 0.670 |
Why?
|
| Arthritis | 1 | 2020 | 81 | 0.670 |
Why?
|
| Myofibroblasts | 3 | 2019 | 78 | 0.660 |
Why?
|
| Monocytes | 1 | 2022 | 347 | 0.650 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.640 |
Why?
|
| Rheumatology | 4 | 2024 | 126 | 0.640 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2019 | 2 | 0.640 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2015 | 123 | 0.620 |
Why?
|
| Bleomycin | 7 | 2024 | 153 | 0.610 |
Why?
|
| Naphthols | 1 | 2018 | 7 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2017 | 2689 | 0.610 |
Why?
|
| Medical History Taking | 1 | 2019 | 110 | 0.600 |
Why?
|
| Watchful Waiting | 1 | 2019 | 71 | 0.600 |
Why?
|
| Sulfonamides | 2 | 2024 | 270 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 1026 | 0.570 |
Why?
|
| Immunologic Factors | 2 | 2011 | 176 | 0.560 |
Why?
|
| Mice | 20 | 2024 | 17881 | 0.550 |
Why?
|
| Humans | 69 | 2024 | 126330 | 0.540 |
Why?
|
| Autoimmunity | 2 | 2024 | 173 | 0.530 |
Why?
|
| Animals | 25 | 2024 | 34533 | 0.530 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2016 | 14 | 0.510 |
Why?
|
| Strongyloides stercoralis | 1 | 2016 | 23 | 0.510 |
Why?
|
| Strongyloidiasis | 1 | 2016 | 43 | 0.500 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 136 | 0.480 |
Why?
|
| Mice, Knockout | 8 | 2024 | 3777 | 0.470 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1931 | 0.460 |
Why?
|
| Inflammation | 3 | 2024 | 1462 | 0.450 |
Why?
|
| Cell Adhesion | 4 | 2022 | 348 | 0.400 |
Why?
|
| Hypertension, Pulmonary | 3 | 2023 | 442 | 0.400 |
Why?
|
| Hemorrhage | 1 | 2016 | 473 | 0.390 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 877 | 0.390 |
Why?
|
| HLA Antigens | 4 | 2024 | 240 | 0.380 |
Why?
|
| Cytokines | 6 | 2019 | 1306 | 0.380 |
Why?
|
| Rheumatoid Factor | 1 | 2011 | 5 | 0.380 |
Why?
|
| Osteopontin | 1 | 2012 | 50 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 10 | 2024 | 4466 | 0.380 |
Why?
|
| Managed Care Programs | 1 | 2011 | 61 | 0.370 |
Why?
|
| CD58 Antigens | 1 | 2011 | 7 | 0.360 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2011 | 19 | 0.360 |
Why?
|
| CD11b Antigen | 1 | 2011 | 36 | 0.350 |
Why?
|
| CD11c Antigen | 1 | 2011 | 38 | 0.350 |
Why?
|
| Epithelial Cells | 1 | 2015 | 913 | 0.350 |
Why?
|
| Female | 32 | 2024 | 67333 | 0.340 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 219 | 0.340 |
Why?
|
| Genetic Loci | 2 | 2011 | 343 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 2933 | 0.330 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 21 | 0.330 |
Why?
|
| OX40 Ligand | 1 | 2009 | 8 | 0.330 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 34 | 0.330 |
Why?
|
| Male | 34 | 2024 | 62031 | 0.320 |
Why?
|
| Interferon-alpha | 1 | 2011 | 242 | 0.310 |
Why?
|
| Cells, Cultured | 6 | 2019 | 3040 | 0.310 |
Why?
|
| Lung | 2 | 2015 | 1508 | 0.300 |
Why?
|
| Synovial Fluid | 1 | 2008 | 16 | 0.290 |
Why?
|
| Withholding Treatment | 1 | 2008 | 67 | 0.290 |
Why?
|
| Cell Communication | 2 | 2008 | 171 | 0.290 |
Why?
|
| Stress, Psychological | 2 | 2011 | 559 | 0.290 |
Why?
|
| Myositis | 2 | 2024 | 81 | 0.280 |
Why?
|
| Middle Aged | 18 | 2024 | 27031 | 0.270 |
Why?
|
| Glucocorticoids | 3 | 2024 | 391 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 683 | 0.260 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2019 | 7 | 0.260 |
Why?
|
| Antigens, CD | 1 | 2008 | 431 | 0.250 |
Why?
|
| Hospitals, University | 1 | 2005 | 99 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 235 | 0.230 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3457 | 0.220 |
Why?
|
| Phagocytes | 1 | 2024 | 23 | 0.220 |
Why?
|
| Terpenes | 1 | 2024 | 28 | 0.220 |
Why?
|
| Myeloid Cells | 1 | 2024 | 104 | 0.210 |
Why?
|
| Lipoblastoma | 1 | 2023 | 6 | 0.210 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 532 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 328 | 0.210 |
Why?
|
| Liposomes | 1 | 2024 | 190 | 0.210 |
Why?
|
| Adult | 16 | 2024 | 29802 | 0.210 |
Why?
|
| Macrophages, Alveolar | 2 | 2014 | 49 | 0.210 |
Why?
|
| Genotype | 6 | 2011 | 2594 | 0.210 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 31 | 0.200 |
Why?
|
| Collagen | 3 | 2019 | 319 | 0.200 |
Why?
|
| Psoriasis | 1 | 2023 | 46 | 0.200 |
Why?
|
| Antigens, Ly | 1 | 2022 | 34 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 124 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 2 | 2011 | 28 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Biological Products | 1 | 2023 | 128 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.180 |
Why?
|
| Polymorphism, Genetic | 1 | 2024 | 820 | 0.180 |
Why?
|
| Signal Transduction | 7 | 2019 | 4638 | 0.180 |
Why?
|
| Vitamin D | 2 | 2019 | 167 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 111 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 75 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 417 | 0.160 |
Why?
|
| Carbon Tetrachloride | 1 | 2019 | 6 | 0.160 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 21 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2017 | 4874 | 0.160 |
Why?
|
| Disease Progression | 4 | 2024 | 2103 | 0.160 |
Why?
|
| Case-Control Studies | 7 | 2023 | 3341 | 0.160 |
Why?
|
| Iron, Dietary | 1 | 2019 | 16 | 0.160 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2018 | 3 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 109 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 740 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2019 | 210 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 858 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 430 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2020 | 253 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 70 | 0.140 |
Why?
|
| Arthralgia | 1 | 2017 | 56 | 0.140 |
Why?
|
| Apoptosis | 1 | 2024 | 1839 | 0.140 |
Why?
|
| Ustekinumab | 1 | 2017 | 2 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 76 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 126 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 164 | 0.130 |
Why?
|
| Synovial Membrane | 2 | 2007 | 27 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2010 | 1789 | 0.130 |
Why?
|
| Dermis | 2 | 2016 | 25 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2019 | 874 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 98 | 0.120 |
Why?
|
| Methotrexate | 3 | 2023 | 336 | 0.120 |
Why?
|
| Biomarkers | 5 | 2022 | 3153 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2011 | 84 | 0.120 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 42 | 0.110 |
Why?
|
| United States | 7 | 2024 | 10990 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4742 | 0.110 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Biopsy | 1 | 2017 | 1257 | 0.110 |
Why?
|
| Child | 3 | 2024 | 24766 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 1038 | 0.110 |
Why?
|
| Young Adult | 2 | 2024 | 9174 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1551 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 161 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 94 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2017 | 337 | 0.100 |
Why?
|
| Transcriptome | 1 | 2019 | 1013 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 421 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 38 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2012 | 50 | 0.100 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.100 |
Why?
|
| Genetic Markers | 2 | 2011 | 611 | 0.090 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 130 | 0.090 |
Why?
|
| Adolescent | 4 | 2024 | 19548 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 144 | 0.090 |
Why?
|
| France | 1 | 2011 | 81 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 23 | 0.090 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 1969 | 0.090 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 20 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 856 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2024 | 709 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 7 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12380 | 0.080 |
Why?
|
| Interleukin-23 | 1 | 2009 | 12 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 91 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 234 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 1168 | 0.080 |
Why?
|
| Centromere | 1 | 2009 | 73 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 138 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 203 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 108 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2010 | 788 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 93 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 128 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2009 | 122 | 0.080 |
Why?
|
| Leukocytes | 2 | 2010 | 213 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 116 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 508 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 315 | 0.080 |
Why?
|
| Social Support | 1 | 2011 | 350 | 0.080 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Mass Screening | 2 | 2024 | 785 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 106 | 0.070 |
Why?
|
| Alleles | 2 | 2011 | 1625 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2194 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 700 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 3901 | 0.070 |
Why?
|
| Risk Factors | 4 | 2011 | 10375 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 433 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 829 | 0.070 |
Why?
|
| Family | 1 | 2010 | 566 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 331 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1712 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1111 | 0.070 |
Why?
|
| Mutation | 1 | 2020 | 5965 | 0.070 |
Why?
|
| Adherens Junctions | 1 | 2006 | 15 | 0.060 |
Why?
|
| Aged | 6 | 2024 | 19962 | 0.060 |
Why?
|
| Cell Line | 1 | 2011 | 2734 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16517 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1611 | 0.060 |
Why?
|
| Recurrence | 2 | 2010 | 1400 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 385 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 515 | 0.060 |
Why?
|
| Massachusetts | 1 | 2005 | 125 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2106 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 66 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2542 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2005 | 78 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 77 | 0.060 |
Why?
|
| Lipids | 1 | 2008 | 524 | 0.060 |
Why?
|
| rho-Associated Kinases | 2 | 2016 | 53 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 820 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 6175 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2011 | 734 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 1722 | 0.060 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2024 | 2 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 162 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1274 | 0.060 |
Why?
|
| Phenotype | 2 | 2011 | 4323 | 0.060 |
Why?
|
| Walk Test | 1 | 2024 | 25 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 383 | 0.060 |
Why?
|
| Aniline Compounds | 1 | 2024 | 20 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 730 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 626 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 202 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 177 | 0.050 |
Why?
|
| Mesentery | 1 | 2023 | 27 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2024 | 285 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2024 | 89 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 89 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 222 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2022 | 97 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 30 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2003 | 102 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2008 | 531 | 0.050 |
Why?
|
| Tretinoin | 1 | 2022 | 114 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1685 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2549 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2022 | 151 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2020 | 16 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2020 | 20 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 635 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 474 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 362 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 362 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 145 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 435 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 434 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2019 | 58 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 653 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 508 | 0.040 |
Why?
|
| Mastectomy | 1 | 2017 | 67 | 0.040 |
Why?
|
| Androstadienes | 1 | 2017 | 50 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 287 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 603 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 91 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 291 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 44 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 369 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 31 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 386 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 244 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 375 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 110 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 67 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 677 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 20 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 71 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1380 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 129 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2014 | 188 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1341 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 48 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 56 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 239 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 631 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 233 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 807 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 257 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3622 | 0.020 |
Why?
|
| Immunogenetics | 1 | 2011 | 8 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 39 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 608 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 306 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 10 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 60 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 31 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 105 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 79 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1560 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 186 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 153 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 87 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 36 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12681 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 528 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1517 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 14221 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2818 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 469 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 18 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1542 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2070 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1266 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 154 | 0.020 |
Why?
|
| Vinculin | 1 | 2006 | 5 | 0.020 |
Why?
|
| Reticulin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6645 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 467 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1325 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 67 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1454 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 1073 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 340 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2010 | 1512 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 157 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5204 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1020 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 330 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1357 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 3587 | 0.010 |
Why?
|
| Neoplasms | 1 | 2003 | 2807 | 0.000 |
Why?
|